The Food and Drug Administration has approved a new treatment for Hepatitis C, and that could set the stage for some price competition.
The FDA just approved the Viekira Pak, which would cost roughly $84,000 for a 12-week treatment. That's less than the $94,000 for 12 weeks of treatment from rival company Gilead.
The new drug shows impressive signs of effectiveness, according to the FDA, curing more than 90 percent of patients infected with Hepatitis C.
These drugs are generating controversy and complaints about the high cost of medicine.
Beer belly a risk factor for sudden cardiac death
Having a "beer belly" is a big risk factor for what doctors call "sudden cardiac death."
Sudden cardiac death is not the same as a heart attack. It's when the heart beats irregularly.
New research shows those with a higher waist-to-hip ratio had more than double the risk compared to people in the normal range.
Doctors are recommending an immediate lifestyle change, including weight loss, dieting and exercise.
Tom Brokaw's cancer in remission
Former NBC anchor Tom Brokaw's cancer has gone into remission.
The 74-year-old was diagnosed with multiple myeloma in February. Multiple myeloma causes cancer cells to overrun health cells in the bone marrow.
Brokaw said doctors are optimistic the cancer is gone. He's now on maintenance drugs to try to prevent the disease from re-appearing.
Brokaw retired from anchoring in 2004. He's still a special correspondent for NBC.